• Medicated liver damage during pregnancy
en To content

Medicated liver damage during pregnancy

HEALTH OF WOMAN. 2019.9(145): 43–49; doi 10.15574/HW.2019.145.43
E.N. Gopchuk
Shupyk National Medical Academy of Postgraduate Education, Kiev

The significant frequency of drug-related liver damage during pregnancy, the lack of unified approaches to forecasting issues, the standards for diagnosis and drug correction, as well as the underestimation of the risk of disease for pregnancy outcomes characterize this problem as highly relevant and significant for modern obstetrics.

Any drugs in a pregnant woman can cause drug hepatitis, so all of them should be prescribed to pregnant women only for strict clinical indications. In this case, one should take into account the genetic predisposition, history and risk factors for the development of the disease, avoid polypharmacy and adjust the dose and route of administration of the drugs used (especially hormonal ones) based on the state of the liver. If the liver indices deviate from the norm, careful monitoring of drug therapy with a monthly or more frequent determination of the level of serum transaminases, alkaline phosphatase, gamma-glutamyl transpeptidase and bilirubin is necessary.

The tactics of managing pregnant women with drug-induced hepatitis requires high medical responsibility when deciding whether to prolong the pregnancy or to terminate it, on the possibility of breastfeeding, determining the type of delivery, anesthetic management and managing the patient in the postpartum period.

Key words: drug-induced liver damage, hepatotoxicity, pregnant cholestatic hepatosis, acute fatty hepatosis, HELLP-syndrome, estrogens, progestogens, sublingual progesterone, parenteral progesterone, hepatoprotectors.

REFERENCES

1. Tracking Universal Health Coverage: 2017 Global Monitoring Report. 2017. WHO and the International Bank for Reconstruction and Development: 88.

2. Haflidadottir S, Jonasson JG, Norland H et al. 2014. Long-term follow-up and liver-related death rate in patients with non-alcoholic and alcoholic related fatty liver disease. BMC Gastroenterol. 146:166. https://doi.org/10.1186/1471-230X-14-166; PMid:25260964 PMCid:PMC4182763

3. Belovol AN, Knyazkova II. 2019. Klinicheskaya farmakologiya gepatoprotektorov. Liky Ukrainy 5-6 (231-232):18-25.

4. Eremina EYu. 2012. Lekarstvennyie porazheniya pecheni. Gastroenterologiya Sankt-Peterburga. 1:16-23.

5. Babak OYa. 2008. Lekarstvennyie porazheniya pecheni: voprosy teorii i praktiki. Liky Ukrainy 4 (120):83-88.

6. Radzinskiy VE, Totchiev GF. 2011. Polipragmaziya pri lechenii beremennyh zhenschin. Farmateka. 13:10-11.

7. Eremina EYu. Lekarstvennyi gepatit beremennyh. 2014. Internist – proekt dlya distantsionnogo usovershenstvovaniya vrachey. Mart. https://internist.ru/publications/detail/lekarstvennyy-gepatit-u-beremennyh.-eremina-e.yu./

8. Hammad AE. 2016. Women and health security. Wld Hlth Statist. Quart. 49(2):74-7.

9. Zahalna teoriia zdorovia ta zdoroviazberezhennia: kolektyvna monohrafiia, za red. YuD Boichuka. 2017. Kharkiv, Vyd. Rozhko SH: 488.

10. Dudnyk SV, Koshelia II. 2016. Tendentsii stanu zdorovia naselennia Ukrainy. Ukraina. Zdorovia natsii 4(40):67-77.

11. Shchorichna dopovid pro stan zdorovia naselennia, sanitarno-epidemichnu sytuatsiiu ta rezultaty diialnosti systemy okhorony zdorovia Ukrainy, 2017 rik. 2018. MOZ Ukrainy. DU UISD MOZ Ukrainy. Kyiv, MVTs Medinform: 458.

12. Saveleva GM, Suhih GT, Serov VN, Manuhin IB, Radzinskiy VE. 2017. Ginekologiya: natsionalnoe rukovodstvo. M, GEOTAR-Media: 1008.

13. Manuhin IB, Tumilovich LG, Gevorkyan MA, Manuhina EI. 2017. Ginekologicheskaya endokrinologiya: klin. lektsii. M.: GEOTAR-Media: 296.

14. Homeriki SG, Homeriki NM. 2012. Lekarstvennyie porazheniya pecheni: uchebnoe posobie dlya vrachey M.: Forte Print: 40.

15. Maslova AS. 2015. Medikamentoznyie porazheniya pecheni pri lechenii narusheniy reproduktivnoy funktsii u zhenschin. Svit meditsini ta biologii. 3(51):136-142.

16. Holestaticheskiy gepatoz beremennyih: aspektyi sovremennoy taktiki vedeniya beremennosti i rodov. 2014. Zdorove zhenschinyi. 8(94):23-24.

17. Ivashkin VT, Shirokova EN, Maevskaya MV, Pavlov ChS, Shifrin OS i dr. 2015. Klinicheskie rekomendatsii Rossiyskoy gastroenterologicheskoy assotsiatsii i Rossiyskogo obschestva po izucheniyu pecheni po diagnostike i lecheniyu holestaza. RZhGGK. 2:41-57. http://rsls.ru/files/Guidelines-RSLS-Holestasis-2016-01-03.pdf

18. Zaitsev YV. 2017. Vyrusnye hepatytu u zhenshchin reproduktyvnoho vozrasta. Medychni aspekty zdorovia zhinky. 7-8(112-113):47-52.

19. Eremina EYu. 2011. Patologiya organov pischevaritelnoy sistemyi u beremennyih. Lambert Academic Publishing. Germaniya.

20. Howard JW, Jones HW, Wentz AC, Burnett LS. 2017. Novak’s textbook of gynecology. Baltimore: Williams & Wilkins: 919.

21. Ushkalova EA, Tkacheva ON, Chuhareva NA. 2011. Problemy bezopasnosti primeneniya lekarstvennyh sredstv vo vremya beremennosti i kormleniya grudyu. Akusherstvo i ginekologiya. 2:4-7.

22. Rosenstock L, Cullen MR. Brodkin C, Redlich C. 2016. Textbook of Clinical Occupational and Environmental Medicine. 3rd edition. Saunders: 1670.

23. Medved VI. 2017. Medikamentoznaya terapiya vo vremya beremennosti: riski, ogranicheniya, osobennosti. Slovo o zdorove. Vypusk 9 (iyun). https://ozdorovie.com.ua/medikamentoznaya-terapiya-vo-vremya-beremennosti-riski-ogranicheniya-osobennosti/

24. U.S. Food and Drug Administration. Pregnancy labeling. 1979. FDA Drug Bull. 9: 23-24.

25. Hubieva MYu, Vlasov AM, Glagolev SV i dr. 2010. Aktualnyie problemy monitoringa effektivnosti i bezopasnosti meditsinskoy produktsii v RF. Vestnik Roszdravnadzora. 2: 29-41.

26. Shevchenko YuL, Denisova IN, Kulakova VN. 2013. Klinicheskie rekomendatsii, osnovannyie na dokazatelnoy meditsine: per. s angl., 2-e izd., ispr. M, GEOTAR-Media: 1248.

27. Eremina EYu, Gerasimenko AV, Gerasimenko IV. 2013. Lekarstvennyie porazheniya pecheni u beremennyh. Meditsinskiy almanah. 1(25):55-59.

28. Golianovskyi OV, Rubinshtein AM, Bachynska MA. 2015. Efektyvnist kombinovanogo zastosuvannia sublinhvalnoi ta vaginalnoi form mikronizovanogo progesteronu v terapii zahrozy peredchasnyh pologiv. Zdorove zhenshchinу. 8(104):19-24.

29. Radzinskiy VE. 2013. Beremennost i rody pri ekstragenitalnoy patologii. M, GEOTAR-Media: 567.

30. Boris EN, Kaminskiy AV, Sumenko VV, Onischik LN, Serbenyuk AV. 2015. Sravnitelnaya otsenka effektivnosti primeneniya mikronizirovannogo progesterona peroralno, intravaginalno i sublingvalno v tsiklah vspomogatelnyih reproduktivnyih tehnologiy i v I trimestre nastupivshih beremennostey. Zdorove zhenschiny. 3(99):162-164.

31. Homyak NV, Mamchur VI, Homyak EV. 2014. Kliniko-farmakologicheskie osobennosti sovremennyih lekarstvennyih form mikronizirovannogo progesterona, primenyayuschihsya vo vremya beremennosti. Zdorove zhenschiny. 4(90):162-166.

32. Preparaty progesterona v sovremennoy reproduktologii: novyie lekarstvennyie formy – novyie vozmozhnosti. Materialy nauchno-prakticheskoy konferentsii s mezhdunarodnym uchastiem «Aktualnyie voprosy reproduktivnoy meditsiny v Ukraine», 23-24 marta 2017 goda, g. Dnepr. Tematicheskiy nomer mart: 41-42. http://repo.dma.dp.ua/1679/1/40-422-2-3.pdf

33. Tatarchuk TF, Shevchuk TV. 2006. Funktsionalnyie zabolevaniya pecheni v praktike ginekologa. Zdorove zhenschiny. 3(27):250-260.

34. Mehdieva ED. 2016. Gepatoz beremennyh – chto delat. Byulleten meditsinskih Internet-konferentsiy. 6(5):427.

35. Dorofeykov VV, Borisova IV, Tarasova MA, Zhestkova NV i dr. 2017. Laboratornaya diagnostika lekarstvenno-indutsirovannyh porazheniy pecheni pri beremennosti. Translyatsionnaya meditsina. 4(3):35-44.

36. Perricone C, de Carolis C, Perricone R. 2012. Pregnancy and autoimmunity: a common problem. Best Pract. Res. Clin. Rheumatol. 26(1):47-60.

37. Lucena MI, Kaplowitz N, Hallal H et al. 2011. Recurrent Drug-Induced Liver Injury (DILI) with different drugs in the Spanish Registry: The dilemma of the relationship to autoimmune hepatitis. J Нepatol. 19:1136-1142. https://doi.org/10.1016/j.jhep.2010.12.041; PMid:21338638

38. Sidelnikova VM. 2013. Podgotovka i vedenie beremennosti u zhenschin s privychnym nevyinashivaniem: metodicheskie posobiya i klinicheskie protokoly. 3-e izd. M, MEDpress-inform: 224.

39. Karr B, Blekuell R, Azis R. 2015. Rukovodstvo po reproduktivnoy meditsine: per. s angl., redaktor IV Kuznetsova. M, Praktika: 832.

40. Akusherstvo ta ginekologiia: u 4-kh t.: natsionalnyi pidruchnyk za red. akad. NAMN Ukrainy, prof. VM Zaporozhana. K, VSV «Medytsyna»: 1032.

41. Vorobiova II, Zhyvetska-Denysova AA, Tkachenko VB, Rudakova NV, Tolkach SM. 2017. Nevynoshuvannia vahitnosti: suchasni pohliady na problemu (Ohliad literatury). Zdorove zhenshchiny. 3(119):113-117.

42. Martínez-Uña M, Varelа-Rey M, Mestre D et al. 2015. S-Adenosylmethionine increases circulating very-low density lipoprotein clearance in non-alcoholic fatty liver disease. J.Hepatol. 62(3):673–681. https://doi.org/10.1016/j.jhep.2014.10.019; PMid:25457203 PMCid:PMC4336596

43. Mueller M, Thorell A, Claudel T et al. 2015. Ursodeoxycholic acid exerts farnesoid X receptor-antagonistic effects on bile acid and lipid metabolism in morbid obesity. J. Hepatology. 6: 1398-1404. https://doi.org/10.1016/j.jhep.2014.12.034; PMid:25617503 PMCid:PMC4451470